This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
For BeneFIX® (nonacog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
BeneFIX® (nonacog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX can be used for all age groups.1
Individualisation of care matters. BeneFIX® can be used for prophylaxis, on-demand, and/or surgery1.
For long-term prophylaxis against bleeding in patients with severe haemophilia B, the average dose is 40 IU per kg (range 13 to 78 IU per kg) at intervals of 3-4 days. In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.1
Patients receiving long-term prophylaxis with clotting factor concentrates or other novel therapies can still experience breakthrough bleeding events, typically associated with traumatic injuries.2 These bleeding events may require on-demand treatment with additional haemostatic agents such as BeneFIX®.2
Current guidance for the perioperative management of people with haemophilia B includes raising factor levels with clotting factor concentrates including FIX replacement therapy, such as BeneFIX®,to provide adequate coverage for recovery and rehabilitation.3
With more than 20 years' experience treating patients with haemophilia B,1 BeneFIX® is building on Pfizer's proud heritage in haemophilia care.
Click here to learn more about Pfizer's commitment in Haemophilia care.
Access information to help determine adequate dosing for your patient and improve their peak control.
Access resources and additional information that aim to support you and your patients.
Contact us for more information on BeneFIX and download our FAQ for supply and stock related queries.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024